Vascular Grafts Market is projected to expand at a CAGR of 6.86% through 2032, according to DelveInsight

According to data provided by the British Heart Foundation (2025), globally, around 640 million people are living with heart and circulatory diseases across the world. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women were affected.
In 2024, the global market was valued at USD 1,863.09 million and is expected to reach approximately USD 3,153.39 million by 2032, reflecting steady growth driven by several key factors. The rising prevalence of cardiovascular diseases-along with associated risk factors such as hypertension, diabetes, and obesity-is significantly increasing the need for surgical interventions, thereby boosting the demand for vascular grafts.

Additionally, growing awareness of cardiovascular health and the expansion of early screening and diagnostic programs are facilitating timely treatment, further propelling market growth.

DelveInsight's Vascular Grafts Market Insights report offers a comprehensive overview of current and projected market dynamics, covering aspects such as competitive landscape, key market drivers, barriers, trends, and leading companies operating within the vascular grafts industry.

Request for a sample page report @ https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key Takeaways from the Vascular Grafts Market Report

The Vascular Grafts market is expected to witness steady growth from 2025 to 2032, expanding at a moderate CAGR during the forecast period.

According to DelveInsight, North America is projected to remain the leading region in the global vascular grafts market, supported by its advanced healthcare infrastructure, high cardiovascular disease burden, and strong presence of major medical device manufacturers.

Key companies active in the market include BD, Getinge AB, Medtronic plc, B. Braun Melsungen AG, Cardinal Health, Terumo Corporation, W. L. Gore & Associates, Inc., JOTEC GmbH, LeMaitre Vascular, Inc., Perouse Medical, CryoLife, Inc., BIOVIC Sdn Bhd, Abbott, Bentley, BioIntegral Surgical, Cook, Merit Medical Systems, SCITECH, Vascular Graft Solutions, and Healionics, among others.

Recent notable developments include:

*
November 2024: Healionics received FDA Breakthrough Device Designation for its Stargraft Trademark arteriovenous graft, designed to improve dialysis access outcomes by reducing infection and thrombosis risks.

*
January 2024: W. L. Gore & Associates obtained FDA approval for the GORE Registered EXCLUDER Registered Thoracoabdominal Branch Endoprosthesis (TAMBE)-the first off-the-shelf endovascular graft developed for the treatment of complex aneurysmal diseases involving the visceral aorta.

To read more about the latest highlights related to the Vascular Grafts market, get a snapshot of the key highlights entailed in the Global Vascular Grafts Market Report [https://www.delveinsight.com/sample-request/vascular-grafts-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Vascular Grafts Overview

Vascular grafts are specialized surgical implants designed to replace, repair, or bypass damaged or diseased blood vessels, helping to restore proper blood circulation. They are widely used in treating cardiovascular disorders such as aortic aneurysms, peripheral artery disease, coronary artery disease, and dialysis-related vascular complications.

These grafts can be either synthetic, made from materials like expanded polytetrafluoroethylene (ePTFE) or Dacron, or biological, derived from human or animal tissues-with the selection based on the patient's condition and specific clinical needs. In recent years, endovascular approaches such as stent grafting have gained traction, offering minimally invasive alternatives to traditional open surgeries and enabling faster recovery times.

The rising global prevalence of cardiovascular diseases, coupled with growing risk factors such as diabetes, hypertension, obesity, and an aging population, is a major driver of the increasing demand for vascular grafts. Additionally, technological advancements in graft design and materials, the adoption of minimally invasive procedures, and expanding awareness and screening programs for cardiovascular health are further contributing to the market's steady growth worldwide.

Vascular Grafts Market Insights

North America is expected to maintain the largest share of the vascular grafts market in 2024, driven by several key factors. The region faces a high burden of vascular and cardiovascular diseases, supported by a robust healthcare infrastructure and the widespread adoption of advanced surgical techniques, including endovascular repair. Furthermore, the strong presence of leading medical device companies, high healthcare spending, and favorable reimbursement policies contribute to the region's market leadership. Growing awareness of early diagnosis and treatment-particularly for conditions such as abdominal aortic aneurysms-along with an aging population, continues to reinforce North America's dominant position in the global market.

According to the Centers for Disease Control and Prevention (CDC, 2024), approximately 4.9% of U.S. adults were diagnosed with coronary heart disease in 2022, while an estimated 12.1 million Americans were projected to live with atrial fibrillation by 2023. Each year, over 795,000 individuals in the U.S. experience a stroke, including 610,000 first-time cases and 185,000 recurrent events. These conditions, often resulting from vascular blockages or clot-related complications, can lead to long-term damage requiring surgical graft implantation. With the continued rise in age-related and lifestyle-associated risk factors such as diabetes, hypertension, and obesity, the demand for synthetic and biological vascular grafts in North America is anticipated to grow substantially in the coming years.

To know more about why North America is leading the market growth in the Vascular Grafts market, get a snapshot of the Vascular Grafts Market Outlook [https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Vascular Grafts Market Dynamics

According to the British Heart Foundation (2025), an estimated 640 million people worldwide are currently affected by heart and circulatory diseases. Data from 2024 further indicate that coronary (ischemic) heart disease-the most widespread cardiovascular condition-impacts roughly 200 million individuals globally, including 110 million men and 80 million women. Additionally, about 56 million women and 45 million men are stroke survivors, while over 13 million people are living with congenital heart disease, with many cases likely remaining undiagnosed. These conditions often result in vessel damage or obstruction, necessitating surgical repair, replacement, or bypass procedures using vascular grafts (synthetic or biological), thereby driving demand and contributing to market expansion.

Furthermore, rising global awareness and prevention initiatives are fostering early diagnosis, preventive care, and timely treatment of cardiovascular diseases. For example, World Heart Day, led by the World Heart Federation, emphasizes heart health education, preventive practices, and the importance of early screening. Such campaigns actively encourage timely interventions and surgical treatments, including those involving vascular grafts, thereby supporting continued growth of the vascular grafts market.

Vascular Grafts Market Drivers:

*
Rising cases of cardiovascular disorders and associated risk factors

*
Increasing awareness and screening programs

*
Increase in product development activities among the key market players across the globe

Get a sneak peek at the Vascular Grafts market dynamics [https://www.delveinsight.com/sample-request/vascular-grafts-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Vascular Grafts Market Report:

*
Coverage: Global

*
Study Period: 2022 to 2032

*
Key Vascular Grafts Companies: BD, Getinge AB, Medtronic plc., B. Braun Melsungen AG, Cardinal Health, Terumo Corporation, W. L. Gore & Associates, Inc., JOTEC GmbH, LeMaitre Vascular, Inc., Perouse Medical, CryoLife, Inc, BIOVIC Sdn Bhd, Abbott, Bentley, BioIntegral Surgical, Cook, Merit Medical Systems, SCITECH., Vascular Graft Solutions, Healionics, and others.

Which MedTech key players in the Vascular Grafts market are set to emerge as the trendsetter, explore @ Vascular Grafts Companies [https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vascular-grafts-market-is-projected-to-expand-at-a-cagr-of-686-through-2032-according-to-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.